Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares closed last Friday at p1,405. ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The company’s shares opened today at p1,392.50. According ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work with the University of Oxford on a cancer vaccine research program.

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

The University of Oxford and GSK are to work on a vaccine to target cells in the pre-cancerous stage (PA) Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to ...

Pfizer and GSK vaccines will now be required to carry warnings that they may be tied to an increased risk of a rare neurological side effect. © 2024 Fortune Media IP ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

At such a critical moment in US history, we need reporters on the ground ... Pharmaceutical giant GSK and the University of Oxford have teamed up to make a vaccine that targets cells at the ...

January 13, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.